Ablaze Pharmaceuticals Raises $75M via Series A Financing
Ablaze Pharmaceuticals (focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets) raised a $75M Series A financing round. The financing was co-led by Vivo Capital and AdvanTech Capital with participation from RAYZ Investments, Nan Fung Life Sciences, Pivotal bioVenture Partners China, venBio Partners, Samsara BioCapital and Venrock Healthcare Capital Partners. Proceeds from the Series A financing will support Ablaze's establishment of a pipeline of advanced TRT candidates for the treatment of solid tumors, expansion of its leadership team, building up infrastructure for radiopharmaceuticals, and securing further strategic collaborations.
- Radiopharmaceuticals, Contrast Agents
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.